Affiliation:
1. Internal Medicine, Southeast Health Medical Center, Dothan, Alabama, USA
2. Internal Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama, USA
Abstract
Methamphetamine has been documented to be associated with pulmonary hypertension. Past studies have shown the association of methamphetamine abuse with pulmonary hypertension; however, cases of isolated acute to subacute right heart failure secondary to methamphetamine use have not been documented. Acute to subacute right heart failure, secondary to methamphetamine use itself represents a diagnostic challenge as there is no specific protocol in place for evaluation for pulmonary hypertension secondary to methamphetamine use and high degree of suspicion is needed to differentiate it from other cardio-pulmonary conditions. Echocardiographic findings of increased right ventricular systolic pressure along with morphological findings suggesting cardiac remodeling in the setting of methamphetamine use is highly suspicious of acute to subacute right heart failure. Early recognition and management, along with long-term abstinence from methamphetamine use is critical to prevent chronic effects on myocardium and to prevent further cardiac remodeling. Although dedicated cardiothoracic imaging and cardiac catheterization can be beneficial; neither of these modalities are needed to establish the diagnosis and to initiate primary interventions. Computed tomography (CT) scan however would be beneficial in excluding other causes of pulmonary hypertension, such as primary pulmonary conditions and pulmonary embolism.
Publisher
Edorium Journals Pvt. Ltd.
Subject
Music,Ecology, Evolution, Behavior and Systematics,History,General Medicine,Ophthalmology,General Medicine,Pharmaceutical Science,Political Science and International Relations,Sociology and Political Science,Political Science and International Relations,Sociology and Political Science,Sociology and Political Science,Plant Science
Reference10 articles.
1. Cheng Y, Tung CK, Chung AKK, et al. Screening of pulmonary hypertension in methamphetamine abusers (SOPHMA): Rationale and design of a multicentre, cross-sectional study. BMJ Open 2019;9(8):e027193.
2. What is the scope of methamphetamine use in the United States? National Institute on Drug Abuse. 2022. [Available at: https://nida.nih.gov/publications/research-reports/methamphetamine/what-scope-methamphetamine-misuse-in-united-states]
3. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34–41.
4. Ryan JJ, Thenappan T, Luo N, et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ 2012;2(1):107–21.
5. Volkow ND, Fowler JS, Wang GJ, et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One 2010;5(12):e15269.